Prospects of using olokizumab in the treatment of polymyalgia rheumatica: preliminary analysis data
https://doi.org/10.37586/2686-8636-2-2025-265-267
Abstract
BACKGROUND. Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are diseases that develop in people over 50 years of age and often require long—term glucocorticoid (GC) therapy, which is associated with a high risk of side effects. In this regard, it is emergent to search for effective steroid-sparing drugs. Interleukin-6 (IL-6) inhibitors, such as tocilizumab and sarilumab, have already proven efficiency in the treatment of PMR and GCA. However, the availability of these drugs in Russia is limited, what makes the use of a domestic IL-6 inhibitor, olokizumab, promising.
About the Authors
A. D. MeshkovРоссия
Moscow
A. L. Maslyansky
Россия
St. Petersburg
A. V. Torgashina
Россия
Moscow
I. O. Smitienko
Россия
Moscow
P. I. Novikov
Россия
Moscow
E. P. Ilivanova
Россия
St. Petersburg
A. L. Chudinov
Россия
St. Petersburg
E. G. Zotkin
Россия
Moscow
A. V. Naumov
Россия
Moscow
O. N. Tkacheva
Россия
Moscow
Review
For citations:
Meshkov A.D., Maslyansky A.L., Torgashina A.V., Smitienko I.O., Novikov P.I., Ilivanova E.P., Chudinov A.L., Zotkin E.G., Naumov A.V., Tkacheva O.N. Prospects of using olokizumab in the treatment of polymyalgia rheumatica: preliminary analysis data. Russian Journal of Geriatric Medicine. 2025;(2):265-267. (In Russ.) https://doi.org/10.37586/2686-8636-2-2025-265-267
JATS XML



















